On June 3, 2022 Naveris, Inc. reported the presentation of an abstract related to its flagship diagnostic test for TTMV-HPV DNA (NavDx) at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place from June 3 through June 7, 2022 in Chicago and virtually (Press release, Naveris, JUN 3, 2022, View Source [SID1234615533]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Results of TTMV-HPV DNA testing in the NRG-HN002 phase II clinical trial for patients with p16-positive oropharynx cancer treated with intensity-modulated radiation therapy (IMRT), with or without cisplatin chemotherapy, will be shared in the presentation.

Details of the presentation are as follows:

Oral Presentation
Abstract: 6006
Title: Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.
Presenter: Sue S. Yom, M.D., Ph.D., Professor and Vice Chair, Strategic Advisory, Department of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery, Univ. of California San Francisco (UCSF)
Presentation Session Date/Time: The oral presentation will take place on Friday, June 3, 2022 from 3:45 – 6:45 p.m. EDT, during the session titled "Head and Neck Cancer"
Location: In-Person & Live Stream | S406

Following the presentation, the data presented will be available on the Naveris website at View Source